Platelet Activation by Antisense Oligonucleotides (ASOs) in the Göttingen Minipig, including an Evaluation of Glycoprotein VI (GPVI) and Platelet Factor 4 (PF4) Ontogeny

Platelet Activation by Antisense Oligonucleotides (ASOs) in the Göttingen Minipig, including an Evaluation of Glycoprotein VI (GPVI) and Platelet Factor 4 (PF4) Ontogeny

Antisense oligonucleotide (ASO) is a therapeutic modality that enables selective modulation of undruggable protein targets. However, dose- and sequence-dependent platelet count reductions have been reported in nonclinical studies and clinical trials. The adult Göttingen minipig is an acknowledged no...

Full description

Bibliographic Details
Main Authors: Allan Valenzuela, Miriam Ayuso, Laura Buyssens, Chloé Bars, Chris Van Ginneken, Yann Tessier, Steven Van Cruchten
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Pharmaceutics
Subjects:
antisense oligonucleotide (ASO)
Göttingen minipig
glycoprotein VI (GPVI)
platelet factor 4 (PF4)
ontogeny
thrombocytopenia
Online Access:https://www.mdpi.com/1999-4923/15/4/1112

Similar Items

Similar Items